



Cabot Corporation to Demonstrate Innovation in Pharmaceutical Purification and Production at CPhI Worldwide

September 15, 2016

BOSTON – Sept. 15, 2016 – [Cabot Corporation](#), a leading global specialty chemicals and performance materials company, will present and exhibit at CPhI Worldwide 2016, the world's leading pharmaceutical platform taking place October 4-6 in Barcelona, Spain.

As medical technologies and treatments continue to advance, there is an increased need for ultrapure, fully traceable pharmaceuticals. Cabot's NORIT® activated carbon is an important tool in the purification of intermediates and end products for the pharmaceutical industry. With its adsorption capacity for a wide range of impurities, varying from odorous compounds to dark-colored bodies and proteins, activated carbon is used for final polishing to remove residual color and odors. Cabot's activated carbons also meet stringent quality standards and are chosen for their performance and consistency.

At the event, visitors can discover how Cabot can support customers as they increasingly work toward meeting the highest standards of quality for their products. Attendees can also learn about how Cabot can be a partner in product innovation from a very early stage, providing the experience and expertise to meet individual customer needs.

David Flannery, global market segment manager, Pharma, will deliver a technical presentation titled, "An Activated Carbon sample kit to help Process Chemists quickly develop a synthetic scheme to manufacture compounds for clinical trials," on Tuesday, October 4 at 11:00 am in room 2C70. This presentation will discuss how to quickly and efficiently optimize compound purification methods.

"We are dedicated to driving advancements in our customers' applications. As the pharma industry grapples to meet increasing stringent regulatory requirements and bring products to market faster than ever before, we have the experience and product strength to help deliver the purification performance they need," said Bart Genemans, business director EMEA region, Cabot Purification Solutions. "As a technology leader in the purification market, our activated carbon products meet the most stringent global requirements. Combined with our broad experience with strategic product development and commitment to customer support, we are uniquely equipped to help our pharmaceutical customers overcome any challenges they may face."

At stand 7K73 Cabot will showcase its portfolio of activated carbons for pharmaceutical purification and discuss how it helps pharmaceutical customers to safely purify their end-use products, get their products to market faster, and meet today's demanding regulatory requirements. A special spotlight will be put on the company's sample kit for drug development. Attendees can learn more about Cabot's solutions, including:

- **Sample Kit for Drug Development**

Process chemists engaged in early drug development are chartered with a difficult task; they must quickly develop synthetic schemes and pilot procedures to manufacture many promising lead compounds for clinical trials. Cabot has developed an activated carbon sample kit designed to help process chemists quickly and efficiently optimize their purification methods thereby enabling them to develop chemical processes that are safe, reproducible and cost-effective. The compact and convenient kit contains six select grades of activated carbon and is ideal for any lab environment.

- **Medicinal Activated Carbon**

Activated carbon is listed on the World Health Organization's (WHO) Model List of Essential Medicines as an antidote for non-specific poisonings. Cabot's activated carbon is used in over twenty registered products to treat gastro-intestinal issues and acute poisoning. Cabot also provides contract manufacturing services for activated carbon based pharmaceuticals. All manufacturing takes place on dedicated production lines compliant with the regulations set forth by the Current Good Manufacturing Practices (cGMPs).

- **Purification for Active Pharmaceutical Ingredients**

During the production of active pharmaceutical intermediates (API), unwanted byproducts are often formed. Cabot's pharmacopoeia-grade, fully-traceable [activated carbon](#)s are of the highest purity to overcome any impurity leaching into the API, and offer high removal efficiency resulting in low dosing to minimize API losses. Cabot's products meet United States and European pharmacopoeia specifications and are produced under Good Manufacturing Practices.

In addition, Cabot will also showcase how its multifunctional fumed silicas can be used in the discovery, development and manufacturing of pharmaceuticals.

- **High-Purity, Multifunctional Excipients**

Cabot's fumed silicas provide improved flow in pharmaceutical and nutraceutical powders and supplements, which enhances the formulation and

processing performance of tablets and capsules in multiple ways.

To learn more about how Cabot's activated carbon and fumed silica solutions are addressing today's pharmaceutical challenges, please visit stand 7K73.

ABOUT CABOT CORPORATION

Cabot Corporation (NYSE: CBT) is a global specialty chemicals and performance materials company, headquartered in Boston, Massachusetts. The company is a leading provider of [rubber](#) and [specialty carbons](#), [activated carbon](#), [inkjet colorants](#), [cesium formate drilling fluids](#), [fumed silica](#), and [aerogel](#). For more information on Cabot, please visit the company's website at: <http://www.cabotcorp.com>.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in the press release regarding Cabot's business that are not historical facts are forward looking statements that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-K.